DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEKINIST

« Back to Dashboard

Clinical Trials for Mekinist

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01438554	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Active, not recruiting	GlaxoSmithKline	Phase 1	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Active, not recruiting	National Comprehensive Cancer Network	Phase 1	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01438554	Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma	Active, not recruiting	Sidney Kimmel Comprehensive Cancer Center	Phase 1	The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
NCT01553851	GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer	Completed	National Comprehensive Cancer Network	Phase 2	This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
NCT01553851	GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer	Completed	Washington University School of Medicine	Phase 2	This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.

Clinical Trial Conditions for Mekinist

Condition Name

Condition Name for Mekinist
Intervention	Trials
Melanoma	12
Recurrent Melanoma	6
Stage IV Skin Melanoma	6
Stage IIIC Skin Melanoma	6

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mekinist
Intervention	Trials
Melanoma	22
Carcinoma	9
Carcinoma, Non-Small-Cell Lung	7
Lung Neoplasms	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mekinist

Trials by Country

Trials by Country for Mekinist
Location	Trials
United States	335
Canada	7
United Kingdom	6
Germany	5
Netherlands	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mekinist
Location	Trials
California	14
Texas	14
Massachusetts	14
Ohio	13
New York	13

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mekinist

Clinical Trial Phase

Clinical Trial Phase for Mekinist
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	27

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mekinist
Clinical Trial Phase	Trials
Recruiting	34
Not yet recruiting	11
Active, not recruiting	6

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mekinist

Sponsor Name

Sponsor Name for Mekinist
Sponsor	Trials
National Cancer Institute (NCI)	27
Novartis	7
Novartis Pharmaceuticals	6

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mekinist
Sponsor	Trials
Other	47
Industry	31
NIH	27

Export unavailable in trial.
Subscribe for complete access.